Target therapy in treatment of HER2-positive breast cancer
The breast cancer (BC) wins first place in structure of oncological incidence of the female population around the world. The special place is occupied by tumors with a superfluous expression of HER2 of a factor which is defined at 25–30 % of patients. Interest to suchpatients is defined by an aggres...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2016-02-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/103 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The breast cancer (BC) wins first place in structure of oncological incidence of the female population around the world. The special place is occupied by tumors with a superfluous expression of HER2 of a factor which is defined at 25–30 % of patients. Interest to suchpatients is defined by an aggressive course of disease, an early metastasis, resistance to chemo-and hormonotherapy. The main targeted drugs registered in the Russian Federation for treatment of HER2-positive BC is Trastuzumab (herceptin®). The presented review contains data of researches on application of a preparation of herceptin in various schemes of chemotherapy. Studying of a combination of trastuzumab with cytostatics, other targeted drugs proceeds at various stages of tumoral process. |
|---|---|
| ISSN: | 1814-4861 2312-3168 |